UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $14.38 Million Position in Krystal Biotech, Inc. $KRYS

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,697 shares of the company’s stock after acquiring an additional 1,760 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Krystal Biotech were worth $14,383,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in KRYS. Toth Financial Advisory Corp grew its position in Krystal Biotech by 75,083.3% in the second quarter. Toth Financial Advisory Corp now owns 4,511 shares of the company’s stock worth $1,677,000 after acquiring an additional 4,505 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of Krystal Biotech during the 2nd quarter valued at $6,345,000. Hsbc Holdings PLC acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at $3,653,000. Wellington Management Group LLP lifted its stake in shares of Krystal Biotech by 261.2% in the 2nd quarter. Wellington Management Group LLP now owns 36,936 shares of the company’s stock valued at $13,728,000 after purchasing an additional 26,709 shares during the last quarter. Finally, Archer Investment Corp bought a new stake in Krystal Biotech in the second quarter worth $308,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Down 3.6%

KRYS opened at $358.24 on Friday. The stock’s 50 day moving average price is $349.81 and its two-hundred day moving average price is $307.38. The firm has a market capitalization of $10.60 billion, a P/E ratio of 44.89 and a beta of 0.54. Krystal Biotech, Inc. has a 12-month low of $136.73 and a 12-month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. As a group, analysts anticipate that Krystal Biotech, Inc. will post 7.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Bank of America raised their target price on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. TD Cowen raised their price objective on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Chardan Capital upgraded Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Citigroup lifted their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $365.40.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, EVP John Thomas sold 1,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 51,000 shares of company stock worth $17,558,270 in the last ninety days. 13.10% of the stock is currently owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.